The second-best target is Methionine aminopeptidase 1 (MAP11), which is known to be over-expressed in several cancer phenotypes, including non-Hodgkin’s lymphoma [50]; pancreatic ductal adenocarcinoma [51]; and acute lymphoblastic leukemia [52]. This evidence concerns the gene TRAPPC14 and non-Hodgkin lymphoma.